ZBH

Zimmer Biomet Holdings, Inc. (ZBH) - Q1 2026 10-Q Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2026. Zimmer Biomet Holdings, Inc. is a global medical technology company designing, manufacturing, and marketing orthopedic reconstructive products, sports medicine, biologics, extremities, trauma products, and robotic technologies. The company operates through three reportable segments: Americas, EMEA, and Asia Pacific. Notable recent developments include the integration of the Paragon 28 acquisition (closed April 2025) and the Monogram Technologies acquisition (closed October 2025).

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 9.3% year-over-year, driven by the Paragon 28 acquisition (+3.9%), favorable foreign currency exchange rates (+2.5%), and volume/mix growth (+7.2%). The S.E.T. category (Sports Medicine, Upper Extremities, Foot & Ankle) saw the highest growth at 19.5%.
• Profitability: Operating profit rose 27.7% to $373.2 million. This was aided by a favorable $30 million adjustment related to probable U.S. tariff refunds, lower restructuring charges ($6.3M vs $36.0M), and reduced R&D spending.
• Cost Structure: Cost of products sold decreased as a percentage of sales (27.6% vs 28.8%) due to tariff refunds and lower inventory charges, partially offset by step-up costs from the Paragon 28 acquisition. SG&A increased as a percentage of sales (40.7% vs 39.7%) due to variable selling expenses and sales force investments.
• Capital Allocation: The company repurchased $250.1 million of common stock in Q1 2026. Cash and cash equivalents declined by $167.7 million primarily due to share repurchases and contingent consideration payments.

Guidance, Outlook, and Risks

• 2026 Outlook: Management expects full-year 2026 net sales growth of 2.5% to 4.5%. This is driven by market growth, new products, and the Paragon 28 acquisition, partially offset by pricing declines and go-to-market strategy changes. Operating profit is expected to increase due to sales leverage and restructuring savings, though offset by inflation and higher interest expense.
• Tariff Impact: Following a U.S. Supreme Court ruling invalidating IEEPA-based tariffs, the company expects to recover approximately $77 million in previously paid tariffs. A $30 million benefit was recognized in Q1 2026.
• Restructuring: The 2025 Restructuring Plan is expected to result in total pre-tax charges of approximately $155 million by the end of 2027. Approximately $143.1 million has been incurred through March 31, 2026.
• Key Risks:
  • Goodwill Impairment: The Global Foot and Ankle reporting unit's fair value exceeds its carrying value by only ~5%, creating a narrow margin for error.
  • China Operations: Ongoing legal claims from displaced distributors in China related to go-to-market strategy changes could materially impact results.
  • Contingent Consideration: Potential future payments for acquisitions (Paragon 28 and Monogram) range from $0 to $720 million based on milestones.

Investor Verification Checklist

• Verify the timing and amount of the expected $77 million U.S. tariff refund and its impact on future cash flows.
• Monitor the integration progress and revenue contribution of the Paragon 28 and Monogram Technologies acquisitions against guidance.
• Assess the status of litigation claims in China and the potential for additional accruals beyond the current $133.1 million liability.
• Review the progress of the 2025 Restructuring Plan to ensure the projected $175 million in annualized savings is realized by 2027.
• Track the fair value of the Global Foot and Ankle reporting unit to evaluate the risk of future goodwill impairment.